Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Drug Dosing and Estimated Renal Function - Any Step Forward from Effersoe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glomerular Filtration Rate Estimation in Renal and Non-Renal Solid Organ Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Urinary excretion of Tamm-Horsfall protein and epidermal growth factor in chronic nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Exercise training and the progression of chronic renal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circadian rhythms of mineral metabolism in chronic kidney disease-mineral bone disorder

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • L Brandi
  • H Daugaard
  • P K Nielsen
  • L T Jensen
  • C Egsmose
  • K Olgaard
Vis graf over relationer

The effects of intravenous administration of 1 alpha-hydroxycholecalciferol [1 alpha (OH)D3] in combination with CaCO3 and 'low-calcium dialysis' (1.25 mmol/l) on plasma (p) parathyroid hormone (PTH) and biochemical bone markers (osteocalcin, alkaline phosphatase, procollagen type 1 c-terminal extension peptide) were examined in 54 patients on chronic hemodialysis with either normal or elevated PTH. Increasing doses of 1 alpha (OH)D3 were administered intravenously under careful control of p-Ca2+ and inorganic phosphate. Blood samples were obtained 1 week before the start of treatment and then every 2nd week. 20 patients with initially normal PTH levels (23.5 +/- 4.17 pg/ml) and 34 patients with initially elevated PTH levels (301 +/- 45 pg/ml) were followed for up to 88 weeks. The present investigation: demonstrated: (1) 'Low-calcium hemodialysis' (1.25 mmol/l) made it possible to use larger doses of CaCO3 and to reduce the doses of an aluminium-containing oral phosphate binder. A decrease in p-Ca2+ during dialysis was induced, and special care had to focus on the compliance to CaCO3, in order not to aggravate the secondary hyperparathyroidism. (2) The combination of 'low-calcium hemodialysis', CaCO3, and pulse intravenous 1 alpha (OH)D3 prevented the development of secondary hyperparathyroidism in patients with normal PTH levels and induced a long-term suppression of p-PTH (106 +/- 25 pg/ml, 88 weeks) in the patients with secondary hyperparathyroidism. By careful monitoring, severe hypercalcemia and hyperphosphatemia were avoided. There were no indications, clinically or biochemically, of development of adynamic bone disease. (3) Bone lesions were healed and a decrease of the bone mineral content in lumbar spine and femoral neck of patients with both normal and elevated PTH levels prevented. (4) The present results may suggest that PTH might be of influence on that regulation of procollagen type 1 c-terminal extension peptide.

OriginalsprogEngelsk
TidsskriftNephron Extra
Vol/bind74
Udgave nummer1
Sider (fra-til)89-103
Antal sider15
ISSN1660-8151
StatusUdgivet - 1996

ID: 51473224